News

Enlarge image

FundingBelgium

Fresh funds for Galapagos

31.01.2013 - Belgian Galapagos NV has secured €2.5m from Flemish IWT to screen for new compounds to treat inflammatory bowel disease (IBD).

The goal of the 2.5-year project is to find new compounds  against IBD, a chronic, uncontrolled inflammation of the intestinal mucosa such as Crohn's disease and ulcerative colitis. The Mechelen-based company already runs a Phase I programme termed GLPG0974 that reduces migration of neutrophils by targeting GPR43 (FFA2).

The purpose of the IWT-funded program is to improve its understanding of the roles of GPR43 and two other undisclosed targets in the pathobiology of chronic inflammatory disorders. Galapagos will collaborate in this project with Professor Dr Paul Rutgeerts and Professor Dr Séverine Vermeire from the Catholic University of Leuven, and the research group of Professor Dr Martine De Vos at Ghent University.  

The 2010 winner of the European Biotechnica Award has also partnered and unpartnered programmes in rheumatoid arthritis (RA). "After RA, IBD is the second autoimmune disease focus for Galapagos. With this grant we will gain a better understanding of the cause of IBD, and this will contribute to the search for better medicines," said Piet Wigerinck, CSO of Galapagos. The current understanding of the pathogenesis of IBD is limited. The characteristic inflammatory response begins with infiltration of neutrophils and macrophages, which release chemokines and cytokines. These in turn exacerbate the dysfunctional immune response and activate cellular and humoral responses in the gut mucosa.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/fresh-funds-for-galapagos.html

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)5.70 SEK21.54%
  • QIAGEN NV (D)23.48 EUR12.29%
  • MOBERG PHARMA (S)44.10 SEK10.25%

FLOP

  • MOLOGEN (D)1.81 EUR-11.71%
  • NICOX (F)9.62 EUR-8.29%
  • SAREUM HOLDINGS (UK)0.72 GBP-6.49%

TOP

  • PROTHENA PLC (IE)55.05 USD57.5%
  • DIAMYD MEDICAL -B- (S)5.70 SEK37.3%
  • VERNALIS (UK)44.50 GBP31.9%

FLOP

  • MOLOGEN (D)1.81 EUR-38.4%
  • SANTHERA (CH)56.20 CHF-26.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)33.00 SEK1975.5%
  • NICOX (F)9.62 EUR428.6%
  • SAREUM HOLDINGS (UK)0.72 GBP213.0%

FLOP

  • BB BIOTECH (D)44.83 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.80 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 30.07.2016